Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. UroGen Pharma Ltd.
  6. News
  7. Summary
    URGN   IL0011407140

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about UROGEN PHARMA LTD.
11:01aUroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
AQ
05/16UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
BU
05/16UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
AQ
05/13UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
BU
05/10TRANSCRIPT : UroGen Pharma Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Develop..
BU
05/10UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Loss $-1.25, vs. Street Est of $-1.25
MT
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $13.6M, vs. Street Est of $15.2M
MT
05/10UroGen Pharma Ltd. Provides Revenue Guidance for the Full Year 2022
CI
05/03UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
BU
04/27Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target
MT
04/26Oppenheimer Adjusts UroGen Pharma Price Target to $21 From $30, Maintains Outperform Ra..
MT
03/29UroGen Pharma Says It Secured FDA Clearance for Phase 1 Trial of Investigational Bladde..
MT
03/29UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy..
BU
More most relevant news
All news about UROGEN PHARMA LTD.
11:01aUroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
AQ
05/16UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
BU
05/16UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
AQ
05/13UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
BU
05/10TRANSCRIPT : UroGen Pharma Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Develop..
BU
05/10UROGEN PHARMA LTD. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/10UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Loss $-1.25, vs. Street Est of $-1.25
MT
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $13.6M, vs. Street Est of $15.2M
MT
More news
News in other languages on UROGEN PHARMA LTD.
05/10UroGen Pharma Ltd. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/10Earnings Flash (URGN) UROGEN PHARMA affiche un chiffre d'affaires de 13,6 millions de d..
05/10UroGen Pharma Ltd. fournit des prévisions de revenus pour l'ensemble de l'année 2022
03/29UroGen Pharma annonce l'approbation par la FDA de la demande de IND pour l'immunothérap..
03/22Phathom Pharmaceuticals nomme Molly Henderson directrice financière et commerciale
03/21UroGen Pharma Ltd. annonce ses résultats pour le quatrième trimestre clos le 31 décembr..
03/21Earnings Flash (URGN) UROGEN PHARMA affiche un revenu de 16,2 millions de dollars pour ..
03/21UroGen Pharma Ltd. annonce ses résultats pour l'année complète se terminant le 31 décem..
03/01UroGen Pharma dépose une demande de nouveau médicament auprès de la FDA américaine pour..
03/01Urogen Pharma Ltd. Soumission d'une demande d'autorisation de mise sur le marché d'un n..
More news
Analyst Recommendations on UROGEN PHARMA LTD.
04/27Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target
MT
04/26Oppenheimer Adjusts UroGen Pharma Price Target to $21 From $30, Maintains Outperform Ra..
MT
03/22Goldman Sachs Adjusts UroGen Pharma's Price Target to $11 from $10, Maintains Neutral R..
MT
03/22HC Wainwright Adjusts UroGen Pharma's Price Target to $26 From $34, Reiterates Buy Rati..
MT
01/18HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rati..
MT
More recommendations
Press releases
11:01aUroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
AQ
05/16UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
BU
05/16UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
AQ
05/13UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
BU
05/10UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Develop..
BU
More press releases
Upcoming event on UROGEN PHARMA LTD.
08/15/22Interim 2022 Earnings Release (Projected)
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs